FDA approves Pfizer’s Velsipity as ‘oral, once-daily pill’ for ulcerative colitis

The FDA has approved Pfizer’s 2 mg once-daily Velsipity, an oral, selective sphingosine-1-phosphate receptor modulator, to treat adult patients with moderately to severely active ulcerative colitis, according to a company press release.
This approval designates Velsipity (etrasimod) as only the second S1P receptor modulator available for the treatment of UC since Zeposia (Ozanimod, Bristol Myers Squibb) was approved for the indication in 2021.
“Velsipity provides adults living with moderately to severely active UC the opportunity to achieve steroid-free remission with an oral,

The FDA has approved Pfizer’s 2 mg once-daily Velsipity, an oral, selective sphingosine-1-phosphate receptor modulator, to treat adult patients with moderately to severely active ulcerative colitis, according to a company press release.
This approval designates Velsipity (etrasimod) as only the second S1P receptor modulator available for the treatment of UC since Zeposia (Ozanimod, Bristol Myers Squibb) was approved for the indication in 2021.
“Velsipity provides adults living with moderately to severely active UC the opportunity to achieve steroid-free remission with an oral,